The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818).
Takayuki Yoshino
Consultant or Advisory Role - Takeda
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Takeda; Yakult
Research Funding - Bayer; Daiichi Sankyo; ImClone Systems; Taiho Pharmaceutical
Kentaro Yamazaki
No relevant relationships to disclose
Motoki Yoshida
No relevant relationships to disclose
Mark Daniel Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Naoto Yoshizuka
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Atsushi Ohtsu
Consultant or Advisory Role - Chugai Pharma; Daiichi Sankyo; Novartis; Taiho Pharmaceutical; Takeda
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Merck Serono; Pfizer; Taiho Pharmaceutical; Takeda; Yakult